Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.45 |
| ▸ | BACE1 | P56817 | 4/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598789 | 0.78 | BACE1 (0.69) | TLR8BACE1NUDT1CXCR4 | |
| SCHEMBL3498573 | 0.76 | BRD4 (0.47) | TLR8BACE1NUDT1ITK | |
| SCHEMBL6273772 | 0.75 | BACE1 (0.44) | TLR8BACE1NUDT1ADORA2ANOS1 | |
| SCHEMBL3498905 | 0.75 | CNR2 (0.52) | TLR8BACE1NUDT1CXCR4 | |
| SCHEMBL1982004 | 0.74 | CXCR4 (0.73) | TLR8CXCR4 | |
| SCHEMBL3499154 | 0.74 | TLR8 (0.50) | TERTTLR8BACE1NUDT1CXCR4 | |
| SCHEMBL6273966 | 0.70 | ITK (0.45) | ADORA2AITK | |
| SCHEMBL12598790 | 0.70 | BACE1 (0.54) | TLR8BACE1NUDT1CXCR4 | |
| SCHEMBL14447547 | 0.70 | TLR8 (0.51) | TLR8BACE1NUDT1CXCR4 | |
| SCHEMBL6276876 | 0.70 | MEN1 (0.39) | BACE1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20050165007-A1 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050124638-A1 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2004050035-A2 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165007-A1 | Benzimidazoles and analogs thereof as antivirals | ZC3HAV1, NXF1, ZC3HAV1L | TERT 3536/4885CCNA2 217/4885CDK2 247/4885 |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | TERT 3536/4885CCNA2 217/4885CDK2 247/4885 |
| US-20050124638-A1 | Benzimidazoles and analogs thereof as antivirals | ZC3HAV1, NXF1, ZC3HAV1L | TERT 3536/4885CCNA2 217/4885CDK2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.